Study of Placebo Without Deception Versus Standard Antidepressant for Major Depressive Disorder

• ClinicalTrials.gov Identifier: NCT01650740
• Recruitment Status: Terminated
• First Posted: July 26, 2012
• Last Update Posted: December 23, 2014
• Sponsor: Sunnybrook Health Sciences Centre
• Information provided by (Responsible Party): Sunnybrook Health Sciences Centre

Tracking Information

• First Submitted Date: July 24, 2012
• First Posted Date: July 26, 2012
• Last Update Posted Date: December 23, 2014
• Study Start Date: August 2012
• Actual Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: July 24, 2012): >= 50% improvement in Montgomery-Asberg Depression Rating Scale (MADRS) Scores (MADRS Response) [ Time Frame: 12 weeks ]
• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: July 24, 2012)

• MADRS remission [ Time Frame: 12 weeks ]
• Credibility and Expectancy Scale (CES) [ Time Frame: Baseline ]

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of Placebo Without Deception Versus Standard Antidepressant for Major Depressive Disorder
• Official Title: A Randomized Trial of Sequenced Treatment Using Placebo Without Deception Followed by Open-Label Antidepressant Versus Immediate Open-Label Antidepressant Treatment for Major Depressive Disorder
• Brief Summary: In recent years, there has been growing evidence that antidepressants are only marginally effective compared to placebo for mild to moderate depression. In other words, although many people improve when they take antidepressant medications, almost as many get better with placebo pills. One possible solution to this problem would be to give patients a trail of a placebo prior to giving them an antidepressant, however there are ethical issues with doing this deceptively. New evidence from other placebo-responsive disorders such as irritable bowel syndrome shows that people may benefit from placebos even if they know they are taking them. This study aims to determine whether giving placebos without deception to people with major depressive disorder followed by the option to switch to an antidepressant is an effective strategy. There will be 3 groups of subjects. The first group is a standard treatment arm and will receive duloxetine, an antidepressant. The second will be given a placebo with the option to switch to duloxetine if they do not improve. The third group will receive supportive clinical visits the option to switch to duloxetine if they do not improve. This design will allow us to determine whether a sequenced treatment of a placebo without deception and then the option to switch to an antidepressant is a viable strategy. It will also help us to determine to what degree the benefit comes from the ritual of receiving and taking the placebo tablet versus the benefit of visits with a doctor alone. The primary hypothesis is that there will be a less than 5% difference between response rates after 12 weeks in the sequenced placebo-then-antidepressant treatment group (both subjects who have remained on placebo as well as those who have switched to the antidepressant will be considered as one group) compared to the immediate antidepressant therapy group.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Not Applicable
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Single (Outcomes Assessor); Primary Purpose: Treatment
• Condition: Major Depressive Disorder

Intervention

• Drug: Duloxetine
  30 mg daily x 1 week followed by 60 mg daily
  Other Name: cymbalta
• Drug: placebo
  small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
• Other: Study visits only
  Weekly visits x 4 weeks followed by visits every 2 weeks

Study Arms

• Experimental: Open-label duloxetine
  12 week treatment with duloxetine
  Intervention: Drug: Duloxetine
• Experimental: Open-label Placebo
  4 weeks of open label placebo with option to continue or switch to duloxetine for remaining 8 weeks.
  Intervention: Drug: placebo
• Experimental: Supportive clinical management
  4 weeks of supportive clinical management visits with option to continue or switch to duloxetine for remaining 8 weeks.
  Intervention: Other: Study visits only

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Terminated
• Actual Enrollment (submitted: December 19, 2014): 1
• Original Estimated Enrollment (submitted: July 24, 2012): 90
• Actual Study Completion Date: November 2014
• Actual Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Provision of written informed consent
• Diagnosis of major depressive disorder, currently depressed as determined by DSM-IV diagnostic criteria (confirmed using the MINI)
• Both females and males, aged 18 to 65 years
• Outpatient status
• Female patients of childbearing potential must have a negative urine human chorionic gonadotropin (hCG) test at enrolment and must be taking or willing to take some acceptable form of birth control during the course of the study if they are or plan to be sexually active
• A grade 8 English comprehension, the ability to understand and comply with the requirements of the study and capable of providing informed consent
• 17-item Hamilton Depression Rating Scale (HAM-D) score of 14-22 at screening and at baseline

Exclusion Criteria:

• Diagnosis of a past hypomanic, manic or mixed state.
• Current or past psychotic symptoms
• Substance or alcohol dependence at enrolment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV criteria
• Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrolment
• Any pervasive developmental disorder (according to DSM-IV criteria)
• Diagnosis of dementia (according to DSM-IV criteria)
• Is at significant risk for suicide, as defined by a score of ≥ 2 on the suicide item of the MADRS, any suicidal ideation with intent or a plan within the 3 months prior to study entry or in the opinion of the investigator.
• Any history of lifetime suicide attempts
• Current treatment with an antidepressant medication
• Treatment with an antipsychotic, mood stabilizer or other psychoactive medication within a period of 5 half-lives of the medication prior to baseline visit
• Known intolerance, hypersensitivity or lack of response to duloxetine as judged by the investigator
• A history of treatment resistant depression (defined as 2 or more failed lifetime trials of antidepressant medication as judged by the investigator)
• Currently undergoing psychotherapy that was initiated within the past 3 months
• Significant medical condition that would contraindicate the use of duloxetine or that is untreated and would need urgent attention (as determined by treating physician)
• Medical conditions that would significantly affect absorption, distribution, metabolism, or excretion of duloxetine
• Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension) as judged by the investigator
• Any clinically significant deviation from the reference range in clinical laboratory test results as judged by the investigator
• Pregnancy (or female of child-bearing age not using adequate contraception) or lactation
• A positive β-hCG test at enrolment
• Involvement in the planning and conduct of the study
• Previous enrolment or randomisation of treatment in the present study
• Participation in another drug trial within 4 weeks prior enrolment into this study or longer in accordance with local requirements

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 65 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada

Administrative Information

• NCT Number: NCT01650740
• Other Study ID Numbers: 081-2012
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: Sunnybrook Health Sciences Centre
• Study Sponsor: Sunnybrook Health Sciences Centre
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Sunnybrook Health Sciences Centre
• Verification Date: December 2014